Erratum: Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications (PLoS ONE (2016) 9:7 (e101783) DOI:10.1371/journal.pone.0101783);Variation in the circumsporozoite protein of Plasmodium falciparum: Vaccine development implications

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Gandhi, Kavita ^a   Thera, Mahamadou A ^b   Coulibaly, Drissa ^b   Traoré, Karim ^b   Guindo, Ando B ^b   Ouattara, Amed ^a   Takala Harrison, Shannon ^a   Berry, Andrea A ^a   Doumbo, Ogobara K ^b   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b and Technologies of Bamako   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; MALARIA VACCINE; PROTOZOAL PROTEIN;

AGE DISTRIBUTION; ARTICLE; ASYMPTOMATIC INFECTION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CS GENE; GENE SEQUENCE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; IMMUNOGENICITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALI; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE IMMUNITY; PARASITE INCIDENCE; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; DNA SEQUENCE; FEMALE; GENETICS; IMMUNOLOGY; INFANT; MALE; METABOLISM; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84903790969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148240     Document Type: Erratum

References (31)

1. Takala SL, Plowe CV (2009) Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 31: 560-573. PIM1138 [pii];10.1111/j.1365-3024.2009.01138.x [doi].
2. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, et al. (2007) Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 4: e93.
3. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, et al. (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development. Sci Transl Med 1: 2ra5.
4. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013. 10.1056/NEJMoa1008115 [doi].
5. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, et al. (2013) Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511-519. jis709 [pii];10.1093/infdis/jis709 [doi].
6. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, et al. (1993) Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49: 166-173. (Pubitemid 23267573)
7. Nardin EH, Nussenzweig RS, McGregor IA, Bryan JH (1979) Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science 206: 597-599. (Pubitemid 10192172)
8. Escalante AA, Grebert HM, Isea R, Goldman IF, Basco L, et al. (2002) A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas-XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol 125: 83-90. (Pubitemid 35449248)
9. de GA, Johnson AH, Maloy WL, Quakyi IA, Riley EM, et al. (1989) Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. Journal of Immunology 142: 4000-4005.
10. Weedall GD, Preston BM, Thomas AW, Sutherland CJ, Conway DJ (2007) Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol 37: 77-85. S0020-7519(06)00319-5 [pii];10.1016/j.ijpara.2006.09.001 [doi].
11. Chenet SM, Branch OH, Escalante AA, Lucas CM, Bacon DJ (2008) Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J 7: 93. 1475-2875-7-93 [pii];10.1186/1475-2875- 7-93 [doi].
12. Jalloh A, Jalloh M, Matsuoka H (2009) T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution? Malar J 8: 120. 1475-2875-8-120 [pii];10.1186/1475-2875-8-120 [doi].
13. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-2532. NEJMoa0807381 [pii];10.1056/NEJMoa0807381 [doi].
14. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-1551. S0140-6736(07)61542-6 [pii];10.1016/S0140-6736(07) 61542-6 [doi].
15. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420. (Pubitemid 39370716)
16. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927-1934. (Pubitemid 34072872)
17. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295. 10.1056/NEJMoa1208394 [doi].
18. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875. 10.1056/NEJMoa1102287 [doi].
19. Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, et al. (2003) Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 68: 97-101. (Pubitemid 38234855)
20. Waitumbi JN, Anyona SB, Hunja CW, Kifude CM, Polhemus ME, et al. (2009) Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS ONE 4: e7849. 10.1371/journal.pone.0007849 [doi].
21. Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, et al. (2002) Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 67: 604-610. (Pubitemid 36014916)
22. Williams R, Peisajovich SG, Miller OJ, Magdassi S, Tawfik DS, et al. (2006) Amplification of complex gene libraries by emulsion PCR. Nat Methods 3: 545-550. nmeth896 [pii];10.1038/nmeth896 [doi].
23. Gandhi K, Thera MA, Coulibaly D, Traore K, Guindo AB, et al. (2012) Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg 86: 775-781. 86/5/775 [pii];10.4269/ajtmh.2012.11-0478 [doi].
24. Rice P, Longden I, Bleasby A (2000) EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16: 276-277. S0168-9525(00)02024-2 [pii].
25. Ochola LI, Tetteh KK, Stewart LB, Riitho V, Marsh K, et al. (2010) Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol 27: 2344-2351. msq119 [pii];10.1093/molbev/msq119 [doi].
26. Enosse S, Dobano C, Quelhas D, Aponte JJ, Lievens M, et al. (2006) RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 1: e5. 10.1371/journal.pctr.0010005 [doi].
27. Schofield L (1990) The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? Bull World Health Organ 68 Suppl: 66-73.
28. Kumkhaek C, Phra-Ek K, Renia L, Singhasivanon P, Looareesuwan S, et al. (2005) Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol 175: 3935-3939. 175/6/3935 [pii].
29. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, et al. (1998) Association of malaria parasite population structure, HLA, and immunological antagonism [see comments]. Science 279: 1173-1177. (Pubitemid 28164361)
30. Doolan DL, Southwood S, Chesnut R, Appella E, Gomez E, et al. (2000) HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocyticstage antigens restricted by multiple HLA class II alleles. J Immunol 165: 1123-1137. ji-v165n2p1123 [pii].
31. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, et al. (1997) Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7: 97-112. (Pubitemid 27357268)